It is noteworthy that the CNS therapeutic effect of fingolimod in MS is mainly mediated by the inhibition of S1P receptors on astrocytes, so that astroglial S1P deletion eliminates its effect (117). This evidence concerns the gene MBTPS1 and myeloid sarcoma.